Vanda Pharmaceuticals Inc (VNDA)
4.56
-0.07
(-1.51%)
USD |
NASDAQ |
Apr 24, 15:41
Vanda Pharmaceuticals Enterprise Value: -121.87M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 23, 2024 | -121.87M |
April 22, 2024 | -112.08M |
April 19, 2024 | -94.25M |
April 18, 2024 | -102.30M |
April 17, 2024 | -86.77M |
April 16, 2024 | -155.24M |
April 15, 2024 | -154.66M |
April 12, 2024 | -151.21M |
April 11, 2024 | -142.00M |
April 10, 2024 | -142.00M |
April 09, 2024 | -137.40M |
April 08, 2024 | -128.77M |
April 05, 2024 | -110.93M |
April 04, 2024 | -105.18M |
April 03, 2024 | -97.70M |
April 02, 2024 | -163.29M |
April 01, 2024 | -151.21M |
March 28, 2024 | -151.78M |
March 27, 2024 | -164.44M |
March 26, 2024 | -166.17M |
March 25, 2024 | -165.59M |
March 22, 2024 | -164.44M |
March 21, 2024 | -163.29M |
March 20, 2024 | -169.62M |
March 19, 2024 | -171.92M |
Date | Value |
---|---|
March 18, 2024 | -172.50M |
March 15, 2024 | -169.05M |
March 14, 2024 | -169.62M |
March 13, 2024 | -167.32M |
March 12, 2024 | -165.02M |
March 11, 2024 | -157.83M |
March 08, 2024 | -165.59M |
March 07, 2024 | -168.47M |
March 06, 2024 | -163.29M |
March 05, 2024 | -150.06M |
March 04, 2024 | -142.58M |
March 01, 2024 | -123.02M |
February 29, 2024 | -131.07M |
February 28, 2024 | -131.07M |
February 27, 2024 | -124.17M |
February 26, 2024 | -125.89M |
February 23, 2024 | -132.22M |
February 22, 2024 | -139.13M |
February 21, 2024 | -138.55M |
February 20, 2024 | -137.98M |
February 16, 2024 | -136.25M |
February 15, 2024 | -136.83M |
February 14, 2024 | -143.73M |
February 13, 2024 | -154.66M |
February 12, 2024 | -139.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-295.40M
Minimum
Nov 09 2023
800.06M
Maximum
Jun 30 2021
241.02M
Average
264.27M
Median
Jun 11 2020
Enterprise Value Benchmarks
ADMA Biologics Inc | 1.572B |
INVO Bioscience Inc | 12.10M |
Johnson & Johnson | 366.81B |
Nektar Therapeutics | -42.88M |
Invivyd Inc | 69.99M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -2.40M |
Revenue (Quarterly) | 45.27M |
Total Expenses (Quarterly) | 52.36M |
EPS Diluted (Quarterly) | -0.04 |
Gross Profit Margin (Quarterly) | 92.36% |
Profit Margin (Quarterly) | -5.30% |
Earnings Yield | 1.15% |
Normalized Earnings Yield | 1.149 |